کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
8795010 1602801 2018 20 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors
ترجمه فارسی عنوان
نتایج واقعی در بیماران مبتلا به دژنراتیو ماکولا مرتبط با سن نوزاد مبتلا به فاکتور مهار کننده فاکتور رشد اندوتلیال عروق داخل وریدی
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی سیستم های حسی
چکیده انگلیسی
Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF agents) have the potential to stabilise or even improve visual acuity outcomes in neovascular age-related macular degeneration (AMD), a sight-threatening disease. Real-world evidence allows us to assess whether results from randomised controlled trials can be applied to the general population. We describe the development of global registries, in particular the Fight Retinal Blindness! registry that originated in Australia, the United Kingdom AMD Electronic Medical Records User Group and the IRIS registry in the USA. Real-world observations relating to efficacy, safety and resource utilisation of intravitreal anti-VEGF therapy for neovascular AMD are then summarised. Novel observations that would have been challenging to identify in a clinical trial setting are then highlighted, including the risk of late disease reactivation, outcomes in second versus first treated eyes, and the increased risk of posterior capsular rupture during cataract surgery in patients who have received intravitreal anti-VEGF therapy. We conclude by exploring future directions in the field. This includes the development of a global consensus on real-world outcome measures to allow greater comparison of results. Real-world neovascular AMD outcome registries can be linked with other databases to determine systemic safety or genetic predictors of treatment efficacy. Machine learning offers opportunities to extract useful insights from “Big Data” often collected in these registries. Real-world registries could be used by drug regulatory authorities and industry as an alternative to more costly and time-consuming phase 4 clinical trials, potentially allowing medication costs to be based on outcomes achieved.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Progress in Retinal and Eye Research - Volume 65, July 2018, Pages 127-146
نویسندگان
, , , , , , , ,